Welcome to our dedicated page for NovoCure SEC filings (Ticker: NVCR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on NovoCure's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into NovoCure's regulatory disclosures and financial reporting.
NovoCure Ltd director Gabriel Leung reported a mandatory sale of 2,945 Ordinary Shares to cover taxes on vested Restricted Stock Units. The shares were sold on an open-market basis at a weighted average price of $15.7707 per share. According to the company’s equity incentive plan, this “sell to cover” transaction was required to satisfy tax withholding obligations and was not a discretionary trade by Leung. After the sale, he directly holds 89,499 NovoCure Ordinary Shares.
NovoCure Ltd director Kristin Stafford reported a mandated sale of 2,945 Ordinary Shares. The shares were sold on June 2, 2026 at a weighted average price of $15.7707 per share to cover tax withholding obligations tied to vesting Restricted Stock Units.
The company’s equity incentive plan requires these tax payments to be funded through a “sell to cover” transaction, so this was not a discretionary trade. After the sale, Stafford directly holds 11,324 Ordinary Shares. The transaction was executed in multiple trades between $15.65 and $15.88 per share.
NovoCure Ltd director Allyson J. Ocean reported a mandated sale of ordinary shares linked to equity compensation. On June 2, 2026, she sold 2,945 ordinary shares at a weighted average price of $15.7707 per share.
According to the disclosure, the shares were sold solely to cover tax withholding obligations from the vesting of Restricted Stock Units under NovoCure’s equity incentive plans and did not represent a discretionary trade. Following this transaction, she directly holds 11,324 ordinary shares of NovoCure.
NovoCure Ltd director Timothy J. Scannell reported an open-market sale of 2,945 Ordinary Shares on June 2, 2026 at a weighted average price of $15.7707 per share. According to the disclosure, these shares were sold to cover tax withholding obligations triggered by the vesting of Restricted Stock Units under NovoCure’s equity incentive plans, and the transaction was mandated by a “sell to cover” provision rather than being a discretionary trade. After this sale, Scannell directly holds 14,288 Ordinary Shares of NovoCure.
NovoCure Ltd director Jeryl L. Hilleman reported a mandated sale of 2,945 ordinary shares. The shares were sold on June 2, 2026 at a weighted average price of $15.7707 per share.
According to the disclosure, the sale was required to cover tax withholding obligations tied to the vesting of Restricted Stock Units under NovoCure’s equity incentive plans and did not represent a discretionary trade. After this transaction, Hilleman directly holds 13,861 ordinary shares of NovoCure.
NovoCure Ltd director Vernon W. Anthony reported an open-market sale of 2,945 Ordinary Shares of NovoCure on June 2, 2026 at a weighted average price of $15.7707 per share. According to the footnotes, these shares were sold to cover tax withholding obligations tied to the vesting of Restricted Stock Units under the company’s equity incentive plans and did not represent a discretionary trade. After this transaction, Anthony directly holds 197,657 Ordinary Shares, indicating the sale was a small, routine adjustment for tax purposes rather than a significant change in his overall position.
NovoCure Ltd director David Hung reported a mandated share sale tied to equity compensation. On June 2, 2026, he disposed of 2,945 Ordinary Shares at a weighted average price of $15.7707 per share.
According to the disclosure, these shares were sold solely to cover tax withholding obligations from vesting Restricted Stock Units under the company’s equity incentive plans, and the transaction "does not represent a discretionary trade". After the sale, Hung directly held 20,465 Ordinary Shares. The sale was executed in multiple trades between $15.65 and $15.88 per share.
Soleus Capital group reports shared beneficial ownership of 10,492,391 ordinary shares of NovoCure Limited, representing 9.1% of the class. The percentage is calculated using 115,820,940 ordinary shares outstanding as of April 24, 2026, per the issuer's Form 10-Q cover. The filing lists the Master Fund and affiliated entities (Soleus Capital, SCG, SCM, Soleus GP) and Guy Levy as reporting persons and disclaims individual beneficial ownership except for Section 13(d) purposes.
Novocure reported first-quarter 2026 net revenues of $174.1 million, up 12% year over year, driven mainly by growth in European Optune Gio patients and contributions from Optune Lua and the Zai Lab partnership in Greater China. Gross margin improved to 78% from 75% as array costs fell.
Higher operating expenses led to a wider net loss of $71.1 million, or $0.62 per share, largely due to a $43 million non-cash share-based compensation charge tied to U.S. FDA approval of Optune Pax. Adjusted EBITDA was slightly negative at $0.3 million.
The company ended March 31, 2026 with $432.0 million in cash, cash equivalents and short-term investments and 4,791 active TTFields patients globally. Regulatory and clinical momentum included U.S. FDA approval and U.S. launch of Optune Pax for locally advanced pancreatic cancer, new coverage decisions in Czechia, British Columbia and Japan, and positive Phase 2 PANOVA-4 data in metastatic pancreatic cancer. Novocure raised 2026 revenue guidance to $690–$710 million and tightened Adjusted EBITDA guidance to a range of $(15) million to breakeven.
NovoCure Limited reported higher revenue but a wider loss for the quarter ended March 31, 2026. Net revenues rose 12% to $174.1 million, driven mainly by international growth in Germany, France and other markets, plus increased U.S. usage of Optune Gio and Optune Lua.
Gross margin improved to 78% as cost per active patient fell, but operating expenses climbed on new indication launches and higher share-based compensation. The company recorded a net loss of $71.1 million, or $0.62 per share, compared with a $34.3 million loss a year earlier.
Adjusted EBITDA narrowed to a small loss of $0.3 million. Active patients on therapy increased to 4,791, supported by the U.S. launch of Optune Pax for locally advanced pancreatic cancer and ongoing expansion of Optune Lua for NSCLC. Cash, cash equivalents and short-term investments totaled $432.0 million, and 115,820,940 ordinary shares were outstanding as of April 24, 2026.